Shares of Pacific Biosciences of California, Inc. (PACB) have traded between $4.37 – 7.5. The next earnings date is set for Feb 10, 2020. Let’s see how its prospects are shaping up.

What does Pacific Biosciences of California, Inc.(PACB) do?

Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

PACB Insider Trading Insight

On 2019-02-19, Phillips James Michael SVP, Research, Development sold 7,231 shares of PACB. That represents a value of $229,530. Not to be outdone, on 2019-02-19, Ordonez Kathy S – Sale sold6,933 shares of PACB. These insiders are clearly in the know because they work closely with the company.

The DY Consensus Price Target

The mean recommendation of Dycom Industries, Inc. from top Wall Street analysts is a Moderate Buy. That is based on 2 analysts who work on the Street. Based on 2 analysts offering 12 month price targets for Dycom in the last 3 months. The average price target is $62.00 with a high forecast of $64.00 and a low forecast of $60.00. The average price target represents a 38.12% increase from the last price of $44.89. Last week, several articles were published in financial papers about DY and 40% Bearish while 60% Bullish.

DY Intraday Trading

DY is due to report earnings on Feb 26, 2020. In the last year the price has ranged from 40.07 – 64.49. Recently, Higgins Patricia sold 2,604 shares of DY. He is a $189,620 shareholder in DY.

Looking for stocks similar to PACB and DY?

Here are some stocks to consider: